MeSH note : a polyvalent vaccine immunotherapy for melanoma of three viable irradiated melanoma
cell lines which contain at least 11 known tumor-associated antigens such as MAGE-1,
MAGE-3, tyrosinase, gp100, gp75, and Mart-1/Melan-A; increased IgM response in patients
receiving vaccine therapy for stage II melanoma was associated with decreased recurrence
and improved survival;